Horizon2020 Grant Awarded to Consortium (Train2Target) Comprising AntibioTx
COPENHAGEN, MAY 16, 2016 – AntibioTx and the Train2Target consortium, comprising leading academic groups and SME’s in the antimicrobial space, has been awarded a Horizon2020 grant to fund research and development. […]
Collaboration Initiated with Prof. Mylonakis (Brown University) to Further Elucidate MoA and New Indication Opportunities
COPENHAGEN, APRIL 07, 2016 – AntibioTx welcomes the collaboration with Professor Mylonakis and foresees it as a very important step towards extracting the compound class potentials. Professor Mylonakis is an expert […]
In vivo Study in Minipigs Confirmed Systemic Safety and No Genotoxicity of ATx201
COPENHAGEN, MARCH 22, 2016 – AntibioTx detected no systemic availability of ATx201 after the application in Hanford minipigs. The study protocol consisted of applying ATx201 twice a day for 28-days, followed […]
AntibioTx Rewarded Grant Funding to Conduct Phase 1 and Phase 2 Studies in Atopic Dermatitis Patients
COPENHAGEN, OCTOBER 26, 2015 – AntibioTx has been rewarded grant funding from The Innovation Fund Denmark to further develop a candidate developed on the basis of extensive compound screening models. […]
